A drug that treats obesity and reduces deaths from heart disease

Extensive research is being conducted by a Danish pharmaceutical company on a novel medication intended to help people *lose weight *and combat obesity The results of the study were remarkable; not only did the medication effectively combat obesity, but it also demonstrated an 18% reduction in mortality risk, potentially making it one of the most significant drugs ever developed.

Based on the results of the tested sample, Novo Nordisk’s new medication, named Wegovy, has already been successful in helping the patient lose weight and lowering their chance of dying by a considerable amount.

The Danish pharmaceutical company wants to persuade additional insurance providers and health systems to cover the cost of this medication.

Novo Nordisk’s senior vice president of development, Martin Holst-Lange, stated that the updated information provided further insight into the drug’s “incredibly powerful” ability to reduce cardiovascular risk.

When Novo Nordisk released preliminary results from its medicine trials in August of last year, investors were so excited about the prospects that the results would entice health systems and insurance companies who had been reluctant to cover this new patient population that the company’s share prices surged by as much as 16%. medicines for weight loss.

Given that Wegovy, the new medication, will set you back more than $1,300 a month, it is deemed costly.

In this Novo Nordisk experiment, nearly 17,600 adults over 45 with obesity and cardiovascular disease but not diabetes were included. During the trial, 375 patients who took Wegovy and 458 patients who took a placebo died, representing an 18% reduction in the chance of death.

This information is provided in response to early findings suggesting patients who took Wegovy had a 20% higher risk of cardiovascular events, such as stroke or heart attack, than those who got a placebo.

According to Lang, the experiment also demonstrated how the medication affects other illnesses, including renal dysfunction. He said, “I anticipate seeing really interesting data regarding the drug’s effect on chronic kidney disease.”